Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Lymphadenopathy is an independent adverse prognostic factor (57% increased risk for disease progression or death) for patients with Waldenström macroglobulinaemia and is found in 33% of patients who have symptomatic disease at the time of diagnosis.”
Title: Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemia
Authors: Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Despina Fotiou, Vassiliki Labropoulou, Nikolaos Giannakoulas, Emmanouil Spanoudakis, Sosanna Delimpasi, Magdalini Migkou, Panagiotis Malandrakis, Michalis Michael, Stavroula Giannouli, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Maria Gavriatopoulou
You can read the Full Article in the British Journal of Hematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
